Labiotech.eu

News and Trends 5 Jun 2015

Abivax launched an Euronext IPO to build up its anti-viral portfolio

Abivax has ended the paperwork and launched its IPO on Euronext Paris, where the biotech company plans to raise €43.6M. The clinical stage biotech is focused on developing anti-viral compounds and human vaccines. The French biotech want to insufflate the raised cash in its three developing products. Data from the two most advanced ones, ABX203 and ABX464, suggest that […]

June 5, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 5 Jun 2015

Novartis declines Gamida’s buyout deal for the second time

Novartis has rejected the Israeli biotech Gamida Cell… again. The Big Pharma has decided not to carry out its option on the Israel-based company. The transaction would have meant a €535.5M deal but it won’t happen, despite Gamida having fulfilled the milestones of the bilateral agreement. Novartis, however, will maintain their collaboration. It is the second time […]

June 5, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 4 Jun 2015

MorphoSys is safe and sound after the promising results of Celgene’s dumped project

MorphoSys has presented at ASCO optimistic results of MOR202’s phase I/IIa study, a candidate treatment against multiple myeloma. The project was doubted after Celgene’s abandon, but now, safety and efficacy data have shown that there is nothing to worry about. MOR202 is a fully human monoclonal HuCAL antibody targeting CD38, a highly expressed and validated target […]

June 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Jun 2015

[Update] AstraZeneca to buy a CAR-T expert?

[Update] Bloomberg announced that they make wrong conclusions from their discussion with AstraZeneca’s CEO Pascal Soriot. The CEO was not talking about the specific acquisition of Juno Therapeutics but about a potential acquisition of a CAR-T expert. Juno’s shares rose as much as 15.8 % just after the rumor was released by Bloomerg. Here is the first version […]

June 4, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 4 Jun 2015

Lesson to Learn from the Best Biotech Entrepreneurs: be a Pioneer!

Last week, Biotech Entrepreneurs gathered in Berlin for the Charité Entrepreneurship Summit 2015. As a spectator, I’ll bring you the most important lessons to take on board from successful entrepreneurs. The First speaker was James Sabry, Senior VP at Genentech, which I already interviewed on the strategy of Genentech/Roche. The Californian entrepreneur, who founded the NASDAQ-listed company Cytokinetics before joining Genentech, gave […]

June 4, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 3 Jun 2015

Erytech successfully completed its Phase III to ‘starve’ cancer cells to death

Erytech Pharma reported optimistic Phase III results of its pivotal program with GRASPA, an original treatment that targets cancer cells through “tumor starvation”. The positive results were presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). Erytech Pharma’s technology makes it possible to “starve” cancer cells by depriving them of […]

June 3, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 Jun 2015

Poor topline results for NeuroVive’s CicloMulsion Phase III

Phase III is a critical step in a drug development process. NeuroVive Pharmaceutical has learned this the hard way. The Swedish company reported unsatisfactory results of CicloMulsion’s phase III clinical trial in patients having gone through a specific type of heart attack known as STEMI (ST-segment elevation acute myocardial infarction). The disappointing topline results are expected to […]

June 3, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 Jun 2015

Avantium’s bioplastic, latest Green Hope for the Agribusiness?

After many awards and famous collaborations, the Dutch biotech company Avantium signed a deal with Tereos for the production of its 100% biobased plastic. The Bioplastic provider is moving forward to disrupt an established market! Initially created as a spin off of Shell, Avantium is a 15 years old Dutch company specialized in the area of advanced […]

June 3, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 3 Jun 2015

Keregen: Winner of the world’s largest Biotech Start-up Accelerator!

OneStart 2015, the world’s largest life sciences and health care startup accelerator program has just rewarded Keregen from the UK with €137.8K (£100K) and Ligadon with €134.6K ($150K) for respectively winning OneStart Europe and OneStart Americas. So, who is this promising European upcomer? Keregen, based in London, develops first-in-class medicines for the prevention and treatment of neurodegenerative […]

June 3, 2015 - 2 minutesmins - By Alexandre Lowrey

News and Trends 2 Jun 2015

Genticel aims to prevent Cancer caused by the Human Papillomavirus

Genticel is a step closer to prevent cancer caused by the human papillomavirus (HPV). The French biotech announced positive results of GTL002’s preclinical in vivo proof of concept, Genticel’s multivalent HPV therapeutic vaccine candidate based on the company’s versatile Vaxiclase platform. Vaxiclase is a technology platform that can be used with many antigens in several […]

June 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Jun 2015

After Failing Phase III, Active Biotech is back to square one

Unfortunately, the Biotech world is not only composed of success stories. Active Biotech, a Swedish company focused on developing treatments for neurodegenerative diseases and cancer. The company, engaged with Ipsen, discontinued a Phase III study and is currently discovering the consequences of this failure the hard way. Active Biotech’s business model, like many small red biotechs, is based on partnering with […]

June 2, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 2 Jun 2015

Immuno-oncology race gets bloodier: BMS is suing its former executive now working for AstraZeneca

Immuno-oncology has gone from a competition to a battlefield. Bristol-Meyer Squibb launched a lawsuit against David Berman, a former researcher that abruptly quit last month after 10 years working for the company’s cancer R&D division. Berman, with his deep knowledge about BMS’s immune-oncology research, headed to AstraZeneca, BMS’ principal opponent. Game on. In this competitive […]

June 2, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Abivax launched an Euronext IPO to build up its anti-viral portfolio

Novartis declines Gamida’s buyout deal for the second time

MorphoSys is safe and sound after the promising results of Celgene’s dumped project

[Update] AstraZeneca to buy a CAR-T expert?

Lesson to Learn from the Best Biotech Entrepreneurs: be a Pioneer!

Erytech successfully completed its Phase III to ‘starve’ cancer cells to death

Poor topline results for NeuroVive’s CicloMulsion Phase III

Avantium’s bioplastic, latest Green Hope for the Agribusiness?

Keregen: Winner of the world’s largest Biotech Start-up Accelerator!

Genticel aims to prevent Cancer caused by the Human Papillomavirus

After Failing Phase III, Active Biotech is back to square one

Immuno-oncology race gets bloodier: BMS is suing its former executive now working for AstraZeneca

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!